// App-Quantinova.ai

e14087 : Evaluation of a spray-dried dispersion (SDD) formulation of MGCD265, a receptor tyrosine kinase (RTK) inhibitor, in a phase 1 study of patients (pts) with advanced solid tumors.

Researchers

Presenter

  • Sunil Sharma

Principal Investigators

  • Geoffrey Shapiro

  • Christian K. Kollmannsberger

  • James Christensen

  • Vanessa Roberts Tassell

  • Demiana Faltaos

  • Richard C. Chao

  • Herbert Hurwitz

Medical Centers

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

  • Dana-Farber Cancer Institute, Boston, MA

  • BC Cancer - Vancouver Centre, Vancouver, BC, Canada

  • Mirati Therapeutics Inc., San Diego, CA

  • Duke University Medical Center, Durham, NC

Locations

  • United States

  • Canada

Companies

  • Mirati Therapeutics

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Hepatocyte growth factor receptor

Drug/Treatment

  • L-Tyrosine

  • MGCD265

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

Phase

  • I

Study Id's

  • NCT00697632

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved